Stay informed about our latest news and updates! Sign up for email alerts here: https://bit.ly/3zXgBLd #Oncology #SolidTumors #PancreaticCancer #CARTcells #DNase
Xenetic Biosciences, Inc.
Biotechnology Research
Framingham, MA 770 followers
Enhancing Lives with Transformative Therapies
About us
Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
- Website
-
http://www.xeneticbio.com/
External link for Xenetic Biosciences, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Framingham, MA
- Type
- Public Company
Locations
-
Primary
40 Speen Street
Suite 102
Framingham, MA 01701, US
Employees at Xenetic Biosciences, Inc.
Updates
-
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers. https://bit.ly/3PUFYGR #Oncology #SolidTumors #PancreaticCancer #CARTcells #DNase
-
Xenetic Biosciences, Inc. Announces Executive Leadership Transition https://bit.ly/3ys98Y9 #Oncology
-
Neutrophil Extracellular Traps (NETs) are a driver of cancer progression and metastasis and can also limit the effectiveness of current cancer therapies. Take a look at our DNase I #oncology platform here: https://bit.ly/43jxnTE #CARTcells #DNase
DNase I Oncology Platform :: Xenetic Biosciences, Inc. (XBIO)
xeneticbio.com
-
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update https://bit.ly/3yaNU0F #Oncology #SolidTumors
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update :: Xenetic Biosciences, Inc. (XBIO)
xeneticbio.com
-
We believe in the power of partnership and collaboration to drive transformative advancements. As passionate advocates of innovation, we understand that together, we can achieve far more than we can alone. If you are interested in partnering, contact info@xeneticbio.com. #Oncology #SolidTumors
-
Backed by an Experienced Team: We are dedicated to advancing innovative immune-oncology technologies and improving lives. Meet them here https://bit.ly/3VSdO37 #Oncology #SolidTumors #PancreaticCancer #CARTcells #DNase
Management Team :: Xenetic Biosciences, Inc. (XBIO)
-
Our lead DNase program, XBIO-015, is initially being developed for pancreatic carcinoma and other solid tumors. #NationalCancerControlMonth #Oncology #SolidTumors #PancreaticCancer #CARTcells #DNase
-
Stay informed about our latest news and updates! Sign up for email alerts here: https://bit.ly/3zXgBLd #Oncology #SolidTumors #PancreaticCancer #CARTcells #DNase
-
Learn more about NETs role in cancer and how our DNase I Oncology Platform is designed to work here: https://bit.ly/43jxnTE #NationalCancerControlMonth #Oncology #SolidTumors #PancreaticCancer #CARTcells #DNase
DNase I Oncology Platform :: Xenetic Biosciences, Inc. (XBIO)
xeneticbio.com